Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysisAntonio D’Alessio, David J. Pinato, Stephen C. Ward et al.|The Lancet Oncology|2024Cited by 64
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumoursCiro Celsa, Fable Zustovich, Giuseppe Cabibbo et al.|Journal of Hepatology|2023Cited by 62
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatmentCiro Celsa, Johann von Felden, Giuseppe Cabibbo et al.|Hepatology|2024Cited by 52
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B DysfunctionClaudia Angela Maria Fulgenzi, Calogero Cammà, Bernhard Scheiner et al.|JAMA Oncology|2024Cited by 37
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse eventsEléonora De Martin, David J. Pinato, Claudia Angela Maria Fulgenzi et al.|Gut|2024Cited by 36